Suresh Kankanwadi

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (6)

• Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era
  Frontiers in Oncology 2023 DOI: 10.3389/fonc.2023.1248723
  +Save
• Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
  BioDrugs 2020 DOI: 10.1007/s40259-020-00406-1
  +Save
• Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma
  Journal of Global Oncology 2019 DOI: 10.1200/jgo.19.00248
  +Save
• Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
  The AAPS Journal 2019 DOI: 10.1208/s12248-019-0349-3
  +Save
• A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects
  British Journal of Clinical Pharmacology 2018 DOI: 10.1111/bcp.13691
  +Save
• A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
  The AAPS Journal 2018 DOI: 10.1208/s12248-018-0249-y
  +Save